P21 is sold as a BDNF-mimetic, TrkB-agonist research peptide intended to cross the blood-brain barrier and support memory, mood and neuroprotection. No PubMed-indexed primary research paper or registered trial describing a compound under this name, sequence or mechanism was located for this entry, and the name collides with the well-studied, unrelated cell-cycle protein p21 (CDKN1A), which dominates search results and makes the marketed compound very difficult to verify.
Ask about P21
Research snapshot
| Peptide category | Marketed as a BDNF-mimetic, TrkB-agonist research peptide |
| Primary research interest | Claimed memory, mood, and neuroprotective support (vendor framing only) |
| Highest available evidence | None identified. No PubMed-indexed paper or registered trial describing a compound matching this name, sequence, or mechanism was located. |
| Human research available | No |
| Development status | Not in any identifiable formal development pathway; sold only through research-chemical vendors |
| Regulatory status | Not approved for human use anywhere |
Technical identity
| Primary name | P21 |
| Alternative names | P021, Peptide 21, P-21 |
| Peptide sequence | Not published in any source identified for this entry |
| Amino-acid length | Not reliably established |
| Molecular formula | Not reliably established |
| Molecular weight | Not reliably established |
| CAS Registry Number | Not reliably established |
| PubChem CID | Not reliably established |
| UNII | Not reliably established |
| DrugBank ID | Not listed |
| Chemical modifications | Not disclosed in any source identified for this entry |
| Peptide class | Claimed BDNF-mimetic / partial TrkB receptor agonist (vendor framing, unverified) |
| Primary biological target | Claimed TrkB receptor (unverified, no indexed research located) |
| Developer or originator | Not identified. No named manufacturer, laboratory, or research group could be traced to a primary source. |
| Development status | Not established |
Note on the name collision: “P21” is also the common short name for p21 (CDKN1A), a well-studied, entirely unrelated cell-cycle regulatory protein with its own large scientific literature. This makes the compound sold under this name very difficult to search for and verify using the name alone.
What this entry can and cannot say
Vendor and forum material describes “P21” as a brain-derived neurotrophic factor (BDNF) mimetic peptide, sometimes described as a partial TrkB receptor agonist intended to cross the blood-brain barrier and support memory, mood and neuroprotection. No PubMed-indexed primary research paper describing a compound named P21 or P021 with that identity, sequence or mechanism was located in the searches run for this entry, and no registered human or animal trial under that name was found on ClinicalTrials.gov.
The name itself is a further complication. “P21” is also the common short name for p21 (CDKN1A), a well-studied cell-cycle regulatory protein with an enormous, unrelated scientific literature; this collision makes the compound circulating under this name difficult to search for and impossible to distinguish from that literature using the name alone.
This entry exists to record that gap honestly rather than to describe a mechanism this site cannot verify. If a specific manufacturer, sequence or primary paper for the compound sold as “P21” becomes identifiable, this entry will be rewritten around it.
Potential benefits and research applications
BDNF-mimetic, memory and neuroprotective claims, none independently verifiable
Vendor and forum material attributes BDNF-mimetic, TrkB-agonist activity to P21, along with memory, mood and neuroprotective benefits modeled on the broader BDNF-signaling literature. No PubMed-indexed paper describing a compound matching this name, sequence or mechanism was located for this entry.
Evidence: unverified. A claim or figure that cannot be traced to an identifiable source; no established or reliably sourced benefit claim was identified for a compound sold under this name.
What dosage information circulates?
Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate. For P21, there is effectively nothing to report: no PubMed-indexed research or registered trial under this name was located for this entry, so no studied dose exists to compare against anything circulating online.
| Reported use or research objective | Route reported | Amount reported | Frequency reported | Reported duration | Evidence or source category |
|---|---|---|---|---|---|
| Cognitive/neuroprotective support, general (vendor framing) | Subcutaneous (per vendor material) | Varies by listing | Varies by listing | Varies by listing | Community/vendor reported: no established or reliably sourced dosing information was identified |
What is not known
Whether a peptide matching the vendor description of P21 has been studied in any published, indexed research, in any species.
The compound’s actual amino acid sequence, molecular identity, or relationship (if any) to published BDNF-mimetic or TrkB-agonist peptide research from other named compounds.
Any human or animal safety, pharmacokinetic or efficacy data whatsoever.
Frequently asked questions
What is P21?
P21 is a name attached to a research peptide sold as a BDNF-mimetic, TrkB-agonist compound. No PubMed-indexed primary research paper describing a compound with this identity was located for this entry.
How does P21 work?
Vendor material claims it acts as a partial TrkB receptor agonist. This mechanism has not been established or independently verified in any indexed research located for this entry.
What dosage has been studied?
No established or reliably sourced dosing information was identified. No primary research under this name was located, so no studied dose exists to report.
What dosage commonly circulates online?
Circulating dosing varies between vendor listings and cannot be checked against a studied dose, because none exists in the sources reviewed for this entry.
Has P21 been studied in humans or animals?
No registered or published study under this name was located in any species.
Is P21 approved for use?
No. It is not approved for human use, and no verifiable identity for the compound sold under this name was established in this entry.
Why is P21 so hard to research?
The name collides with p21 (CDKN1A), a well-studied, entirely unrelated cell-cycle regulatory protein with an enormous separate scientific literature, which makes searching for the marketed compound under this name unreliable.
What routes of administration are reported?
Vendor material describes subcutaneous administration, but no controlled study of any route was located for this entry.
Does P21 improve memory or mood?
This has not been established. No identifiable primary research supporting this claim for a compound under this name was located.
What side effects have been reported?
No safety or adverse-event data exists in the sources reviewed for this entry, because no verified study of this compound was located.
What remains unknown about P21?
Essentially everything: whether a peptide matching the vendor description has been studied at all, its actual amino acid sequence or molecular identity, and any human or animal safety, pharmacokinetic or efficacy data.
Bottom line
P21 is the one entry on this site where the honest answer is that the underlying research could not be located at all. No PubMed-indexed paper, registered trial, or verifiable primary source describing a compound matching the vendor description of P21 was found, and the name’s collision with the unrelated cell-cycle protein p21 (CDKN1A) makes verification especially difficult. Readers should treat any dosage, mechanism, or benefit claim made for a compound sold under this name as unverified until a specific, checkable source is identified.
What circulates E5
| Reported use | Route | Amount reported | Frequency | Reported length |
|---|---|---|---|---|
| Cognitive/neuroprotective support, general | Subcutaneous | Varies by listing | Varies by listing | Varies by listing |
Circulating dosing for P21 varies between listings and cannot be checked against a studied human or animal dose, because no primary research under this name was located for this entry at all. A dose figure with nothing behind it to compare against is not a data point.
Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.
Compare P21 with related compounds
Research area: Neuro and cognitive.